Philochem AG, part of the Philogen Group (MIL:PHIL), and RayzeBio, a subsidiary of Bristol-Myers Squibb (NYSE:BMY), announced ...

Bristol-Myers Squibb Company (NYSE:BMY) is one of the 15 best stocks to invest in for an 18 year old. On June 10, ...

BMS kickstarted its radiopharma drive last year when it completed a $4.1 billion acquisition of San Diego-based RayzeBio, ...

The company is paying $350 million upfront, and potentially over $1.3 billion overall, for a radiopharmaceutical for prostate ...

BMS entered the radiopharma space via its $4.1 billion buyout of RayzeBio at the end of 2023. Unlike Novartis’ approved ...

OncoACP3 is a small molecule ligand with high affinity and specificity for Acid Phosphatase 3 (ACP3), a novel target in ...

Instead of homing in on PSMA—currently the most validated target in prostate cancer—BMS and Philochem will instead ...

Philochem to license worldwide rights to OncoACP3, a novel radiopharmaceutical therapeutic and diagnostic agent targeting prostate cancer to RayzeBio: Otelfingen, Switzerland Thur ...

The $1.35 billion deal is expected to close in Q3 2025, giving RayzeBio rights to the radioligand, which is already undergoing Phase I testing as a diagnostic.

Philochem AG’s ligand-targeting approach drew to the table Bristol Myers Squibb Co. in a potential $1.35 billion agreement granting BMS subsidiary Rayzebio Inc. exclusive worldwide rights to OncoACP3, ...

ZURICH, Switzerland and OXFORD, United Kingdom and MONROE TOWNSHIP, N.J., Dec. 04, 2023 (GLOBE NEWSWIRE) -- Philochem AG, a wholly owned subsidiary of Philogen S.p.A ...

Philochem AG, part of the Philogen Group (MIL:PHIL), and RayzeBio, a subsidiary of Bristol-Myers Squibb (NYSE:BMY), announced on Wednesday that they reached a worldwide licensing agreement.